Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Alhemo

- PMLiVE

Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica

If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica

- PMLiVE

Novo Nordisk UK appoints George Godfrey as Senior Director, Medical & Regulatory

Godfrey previously served as Head of Medical for Respiratory and Immunology for AstraZeneca UK

- PMLiVE

EMA recommends granting marketing authorisation approval for Nezglyal

The treatment is for cerebral adrenoleukodystrophy, a rare neurodegenerative disease

- PMLiVE

AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma

Asthma affects over 360 million people worldwide, including over 40 million people in Europe

- PMLiVE

Novo Nordisk’s Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes

The insulin is designed as an alternative to daily basal insulin

- PMLiVE

Novo Nordisk elects employee representatives to Board of Directors

The elected employee representatives will join the Board of Directors after the annual general meeting on 26 March 2026

- PMLiVE

Novo Nordisk to invest 432m euros to expand manufacturing facility in Ireland

Construction is expected to be completed in phases from the end of 2027 into 2028

- PMLiVE

Novo Nordisk and Vivtex partner in deal worth up to $2.1bn

The companies aim to develop next-generation oral medicines for obesity and diabetes

- PMLiVE

Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic

The reduction in price to $675 will take effect at the beginning of next year

- PMLiVE

AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer

Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually

- PMLiVE

Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease

Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links